Discover why Johnson & Johnson is a top stock pick for income investors in 2025 with strong sales growth and promising ...
Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...
How can you make therapy work best for you? Here are a few tips. And a new study offers more evidence that teens are in trouble.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...